Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Assessing safety and tolerability of MT-5111 in patients with HER2+ tumors

Brian Van Tine • 4 Jun 2022
ASCO 2022
General MT-5111

Brian A. Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, discusses results from a Phase I study (NCT04029922) of MT-511, a novel shiga toxin-conjugated recombinant fusion protein targeting HER2 in HER2-expressing solid tumors. The investigational therapy is well tolerated to-date with no clinically significant immuno- and cardiotoxicity, with the dose-escalation portion of the trial currently being conducted. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Brian Van Tine

0:54
What does the future hold for CAR T-cells in sarcoma management?
Brian Van Tine • 4 Jun 2023
0:33
Predicative biomarkers of response to immunotherapy in STS
Brian Van Tine • 4 Jun 2023
0:50
SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma
Brian Van Tine • 4 Jun 2023
0:57
Cabozantinib with checkpoint inhibition in soft tissue sarcoma
Brian Van Tine • 4 Jun 2023

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals